At its June 9, 2011 meeting in London, the European Medicines Agency’s (EMA) Management Board unanimously elected Kent Woods, Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom, as chair for a three-year mandate.
Accepting his election, Professor Woods told the Board that, “it is my ambition to provide strategic leadership in helping the Agency to continue to protect public and animal health and maintain public trust.”
Proposals for better handling of conflicts of interests
The Board agreed on a way forward for introducing changes to the way the Agency handles potential conflicts of interests of staff members. The proposed changes are aimed at achieving a more robust system for staff, mirroring the same principles on handling conflicts of interest adopted by the Board in October 2010 for committee members and European experts.
Once implemented, the rules will clarify allowable and non-allowable interests for staff, and strengthen controls on the appointment of individuals as product team leaders. The rules will also require new Agency recruits to divest any interests prior to appointment.
The Agency also initiated discussions with the Board to find a common approach for the management of conflicts of interests throughout the EU network.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.